亞甲藍 Methylene Blue × 認知功能

結論:安全性檢視中

獨立判讀為 D(反證據佔主導 + 安全性紅旗):(1) 兩大 AD pivotal phase 3 LMTM RCT(Gauthier 2016 Lancet n=891 ADAS-Cog p=0.

D 🔴 D 反證據 安全審查 low — community discussion mostly non-commercial
⚠️ 標記 🇹🇼 台灣在地警示
⚗️ 安全性檢視中:已有安全疑慮正在評估,本結論尚未定論。

獨立判讀為 D(反證據佔主導 + 安全性紅旗):(1) 兩大 AD pivotal phase 3 LMTM RCT(Gauthier 2016 Lancet n=891 ADAS-Cog p=0.9834/0.9323;Wilcock 2018 n=800)皆未達預設 primary endpoint,所有正面 AD 訊號僅來自 TauRx-sponsored 修改後 post-hoc monotherapy 分析,且 LMTM/HMTM 為亞甲藍還原形衍生物非 parent MB;(2) Hafez 2023 systematic review 雖收 6 RCT n=3822 描述 5/6 正向,但明確記載『largest pivotal phase 3 trials missed pre-specified primary endpoints』且 industry COI;(3) 唯一正向訊號為小型急性研究(Rodriguez 2016 n=26 fMRI memory +7% p=0.01;Telch 2014 n=42 contextual memory d=0.68,且 high-fear subgroup 反向 d=-0.63 有害訊號)與 Yang 2021 圍術期 IV POCD(n=248 open-label OR 0.30)— 三者皆為小樣本、急性/單次給藥、利基情境,無一支持『慢性口服日常 nootropic』使用;(4) 至今無任何 chronic-dosing MA 評估健康/MCI 族群之認知效益;(5) Harvard Health 2025 明文指出『記憶研究相近劑量反使腦血流降約 8%』— 此為與宣稱機轉相反之直接反證;(6) L4 監管面五大機構(FDA Boxed Warning + 2020 三封 COVID warning letters、EFSA/EMA medicinal product only、NHS POM、TFDA 處方藥/罕藥、WHO EML 限 methemoglobinemia、Health Canada/TGA/ANSES 全面限制)一致認定 MB 不得作為補充劑流通;(7) L9 列為 high_risk —— FDA Boxed Warning(與 SSRI/SNRI/MAOI/TCA/triptans/serotonergic opioids/linezolid/St. John's Wort/dextromethorphan/bupropion/buspirone 等併用恐致命血清素症候群),G6PD 缺乏(台灣盛行率 ~3%)絕對禁忌,孕婦 / 哺乳婦女禁用,高劑量反致 methemoglobinemia。

給 D 而非 C:(a) 規模最大、品質最高的 AD 試驗群一致 null;(b) Harvard 提出直接反向機轉證據(腦血流下降);(c) 安全性紅旗多重疊加;(d) 機轉雖合理但 outcome 已被高品質試驗解耦。

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.40
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 安全審查
信心度
77%
證據方向大致一致
證據層級
E3
單篇高品質統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L5 臨床機構權威立場
0.30
L11 AI 複核獨立判讀
0.30
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.403
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — | C→D 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Exploring Methylene Blue and Its Derivatives in Alzheimer's Treatment: A Comprehensive Review of RCTs
PMID: 38022191 2023 系統性回顧 n = 3,822
結論:5 of 6 RCTs reported MB/derivatives improved cognitive performance and reduced amyloid burden; however the largest pivotal Phase 3 trials missed pre-specified primary endpoints, with positive findings emerging mainly from post-hoc monotherapy cohort analyses.
學術資助
前往 PubMed
Efficacy and safety of tau-aggregation inhibitor therapy in mild/moderate Alzheimer's: phase 3 LMTM trial
PMID: 27863809 2016 隨機對照試驗 n = 891
結論:Primary endpoints not met: no significant difference between LMTM 75 mg (p=0.9834) or 125 mg (p=0.9323) versus low-dose control on ADAS-Cog; ADCS-ADL similarly non-significant. Pre-specified add-on hypothesis failed.
🟢 高品質 ⚠️ 廠商資助
前往 PubMed
Potential of Low-Dose LMTM Monotherapy for Mild Alzheimer's: Cohort Analysis as Modified Primary Outcome in Phase III
PMID: 29154277 2018 隨機對照試驗 n = 800
結論:In modified cohort analysis, monotherapy 4 mg BID and 100 mg BID significantly slowed cognitive decline and brain atrophy versus add-on (p<0.025); brain atrophy in monotherapy patients normalised to elderly controls after 9 months. Findings are from a revised post-hoc analysis plan.
🟠 品質有限 ⚠️ 廠商資助
前往 PubMed
Methylene blue reduces incidence of early postoperative cognitive disorders in elderly non-cardiac surgery patients
PMID: 33091706 2021 隨機對照試驗 n = 248
結論:MB markedly reduced POD (7.3% vs 24.2%, OR 0.24, 95% CI 0.11-0.53, p<0.001) and early POCD at day 7 (16.1% vs 40.2%, OR 0.30, 95% CI 0.16-0.57, p<0.001) versus saline; adverse-event profiles comparable. (NCT04341844 / ChiCTR1900020596)
學術資助 效應量:[object Object]
前往 PubMed
Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain
PMID: 27351678 2016 隨機對照試驗 n = 26
結論:MB increased BOLD response in bilateral insular cortex during attention (Z 2.9-3.4, p=0.01-0.008) and in prefrontal/parietal/occipital cortex during memory task (Z 2.9-4.2, p<=0.03); behavioural memory retrieval accuracy improved by 7% versus placebo (p=0.01). Small acute pilot study.
學術資助 效應量:[object Object]
前往 PubMed
Post-Session USP Methylene Blue Facilitates Retention of Pathological Fear Extinction and Contextual Memory in Phobic Adults
PMID: 25018057 2014 隨機對照試驗 n = 42
結論:MB enhanced contextual memory at 1-month follow-up (p=0.047, Cohen's d=0.68); in low post-training-fear subgroup MB also reduced peak fear (p=0.035, d=0.76), but in high-fear subgroup MB tended to worsen retention (p=0.084, d=0.63). State-dependent effect — narrow generalisability.
學術資助 效應量:[object Object]
前往 PubMed

L4a US FDA
謹慎
PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. 來源↗
L4b EU EFSA
反對
Methylthioninium chloride Proveblue is used in adults and children of all ages as an antidote to treat symptoms of methaemoglobinaemia. 來源↗
L4c UK NHS
反對
methylthioninium chloride by the intravenous route is approved only for drug-induced methaemoglobinaemia in adults at a dose of 1–2 mg/kg 來源↗
L4d TW TFDA / 衛福部
反對
該藥品在國內並無許可證……醫院以專案方式進口至國內儲備,以供病患緊急所需使用。 來源↗
L4e WHO
中性
Methylthioninium chloride (methylene blue) — Injection: 10 mg/mL in 10-mL ampoule — listed under Section 4: Antidotes and other substances used in poisonings (4.2 Specific) of the WHO Model List of Essential Medicines (23rd List, 2023). 來源↗

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
反對
A 2023 paper published in the Journal of Cerebral Blood Flow & Metabolism reported that methylene blue (in similar doses studied by researchers at The University of Texas at Austin who claimed the compound had memory-enhancing properties) led to a ∼8% decrease in human brain blood flow. 來源↗
L5e Specialty Society (condition-mapped)
謹慎
not a single food, beverage, ingredient, vitamin or supplement has been proven to prevent, treat or cure Alzheimer's disease or to benefit cognitive function or brain health 來源↗

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 低度
📍立場總覽

台灣社群(PTT/Dcard/Mobile01/痞客邦)幾乎無「亞甲藍用於認知功能/益智」的實質討論。PTT 搜尋結果幾乎全為水族治魚病用途或與主題無關的「藍甲」俚語;認知增強相關內容僅見於英文 nootropic 網站,無在地使用經驗、品牌或副作用反饋可萃取。屬冷門題材,無社群共識。

💬社群實感

無共識(台灣社群幾乎無相關討論)

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

亞甲基藍溶液 養魚專用 500毫升 $129

代表來源 ↗
L10b · TFDA 法定身份 官方認定
⚠️未列管 / 未核准

該藥品在國內並無許可證

來源 ↗

  • 規律身體活動
  • 高血壓的妥善控制
  • 戒菸
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v6 engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-methylene-blue-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-cognitive-function-INT-methylene-blue-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "亞甲藍能改善認知功能",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 1,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🔴 D 反證據"
  }
}